RE:RE:Anti-CTLA-4 vs Anti--PD-(L)1 Immune Checkpoint InhibitorsJanuary 25, 2024 - Adding pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) elicited an overall survival (OS) improvement across multiple subgroups of patients with persistent, recurrent, or metastatic cervical cancer, according to updated findings from the phase 3 KEYNOTE-826 trial (NCT03635567).
“In this randomized clinical trial, the addition of pembrolizumab to chemotherapy with or without bevacizumab improved OS across subgroups of patients with persistent, recurrent, or metastatic cervical cancer,” the study authors wrote. “Additional studies of pembrolizumab combined with anti-TIGIT or anti–CTLA-4 checkpoint inhibitors, bispecific antibody engagers, and cellular-based immunotherapies including tumor-infiltrating lymphocytes and chimeric T-cell receptor antigens, are ongoing.”
https://www.cancernetwork.com/view/pembrolizumab-combo-improves-os-in-metastatic-cervical-cancer-subgroups